Angel Matthew's Form 4 filing
Tempest Therapeutics, Inc. (TPST) · filed Jun 23, 2026
- Accession no.
- 0001193125-26-279703
- Filed
- Jun 23, 2026
- Trade date
- Mar 24, 2026
- Filing delay
- 91 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 2 derivative transactions. Open-market purchases total $500.0K. It was filed 91 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Angel MatthewCIK 0001931356 | Director, Officer (CEO and President), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | Common Stock | PPurchaseAcquired | +231,482 | $2.16F2 | +$500,001.12 | 231,482 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The combined purchase price per one share of Common Stock and accompanying one warrant to purchase one share of Common Stock was $2.16.
Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.
Remarks
This transaction is being reported late due to an inadvertent administrative oversight.